Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3'-phosphatase in a nanoparticle formulation based on the drug delivery technology. The company is headquartered in Calgary, Canada.
Canadian Market Performance
7D7 Days: 0.7%
3M3 Months: 11.2%
1Y1 Year: 17.5%
YTDYear to Date: 10.6%
In the last week, the market has been flat, with a notable exception in the Industrials sector dropping 3.0%. Meanwhile, the market is actually up 18% over the past year. Earnings are forecast to grow by 12% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...